Sugi Predict

Sugi Predict / Compounds / SCHEMBL4973143

SCHEMBL4973143

SCHEMBL4973143

N#Cc1ccc(Br)cc1C=O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 3/20 0.52
▸ MAOB P27338 3/20 0.42
▸ MAOA P21397 2/20 0.42
▸ CYP2A6 P11509 3/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ PTPN1 P18031 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ MCL1 Q07820 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ PIM3 Q86V86 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898053 0.84 ERN1 (0.47) ERN1MAOBMAOACYP2A6PTGDR2
SCHEMBL16955082 0.80 MAOB (0.42) ERN1MAOBMAOAALDH1A1CHEK1
SCHEMBL16961223 0.80 MAOB (0.42) ERN1MAOBMAOAALDH1A1CHEK1
SCHEMBL7195384 0.78 RAD51 (0.40) CYP2A6ALDH1A1
SCHEMBL18397706 0.77 EIF2AK2 (0.45) ERN1MAOBMAOAALDH1A1
SCHEMBL18397705 0.77 EIF2AK2 (0.45) ERN1MAOBMAOAALDH1A1
SCHEMBL29954838 0.76 KDM4E (0.39) ERN1MAOBMAOAPTPN1ALDH1A1
SCHEMBL584206 0.76 ERN1 (0.52) ERN1MAOBMAOACYP2A6PTPN1
SCHEMBL1956935 0.76 KDM4E (0.39) ERN1MAOBMAOAPTPN1ALDH1A1
SCHEMBL29955682 0.76 SRC (0.43) ERN1MAOBMAOACYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382820-B Synthetic method of 3-aryl isoindole derivative Changzhou University (CN) 2019-12-06 — — CN claimed
CN-105111217-A Method for synthesizing isoindole dihyroquinazoline derivative UNIV CHANGZHOU 2015-12-02 — — CN claimed
CN-104876850-A Isoindolinone derivative synthesis method UNIV CHANGZHOU 2015-09-02 — — CN claimed
EP-4051680-B1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2025-09-03 — — EP disclosed
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2025-08-19 — — US disclosed
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 — — US disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 — — EP disclosed
US-20240327380-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2024-10-03 — — US disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 — — CN disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
US-7304059-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2007-12-04 — — US disclosed
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-08-03 — — US disclosed
US-7074799-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-07-11 — — US disclosed
EP-1581225-A1 COMBINATION THERAPY FOR THE TREATMENT OF PAIN NEUROGEN CORPORATION (US) 2005-10-05 — — EP disclosed
EP-1471910-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS NEUROGEN CORPORATION (US) 2004-11-03 — — EP disclosed
US-20040142958-A1 Combination therapy for the treatment of pain NEUROGEN CORPORATION 2004-07-22 — — US disclosed
WO-2004054582-A1 COMBINATION THERAPY FOR THE TREATMENT OF PAIN NEUROGEN CORPORATION (US) 2004-07-01 — — WO disclosed
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION 2004-06-03 — — US disclosed
WO-2003062209-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN NEUROGEN CORPORATION (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327380-A1 BTK INHIBITORS BTK, SYK, LYN ERN1 702/4885MAOB 1936/4885MAOA 2809/4885
US-20040142958-A1 Combination therapy for the treatment of pain OPRK1, OPRL1, OPRM1 ERN1 1100/4885MAOB 1283/4885MAOA 1452/4885
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA ERN1 821/4885MAOB 2161/4885MAOA 2052/4885
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase ABL1, CDK1, CDK2 ERN1 780/4885MAOB 379/4885MAOA 1048/4885
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 ERN1 4532/4885MAOB 1527/4885MAOA 1075/4885
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 ERN1 4434/4885MAOB 1680/4885MAOA 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.